002349.SZ
Jinghua Pharmaceutical Group Co., Ltd. [002349.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002349.SZ Stock Summary
Top 10 Correlated Stocks
002349.SZ
In the News
002349.SZ Financial details
Company Rating
Buy
Market Cap
6.13B
Income
218.27M
Revenue
1.52B
Book val./share
3.11
Cash/share
1.41
Dividend
0.08
Dividend %
0.96%
Employees
1.64K
Optionable
No
Shortable
Yes
Earnings
27 Apr 2021
P/E
31.09
Forward P/E
-
PEG
8.84
P/S
4.45
P/B
2.68
P/C
5.28
P/FCF
25.21
Quick Ratio
4.49
Current Ratio
5.37
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
0.27
EPS next Y
-
EPS next Q
-
EPS this Y
30%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.47%
Revenue last 5Y
3.03%
Revenue Q/Q
-14.43%
EPS Q/Q
-39.17%
-
-
-
-
SMA20
-6.91%
SMA50
-
SMA100
-17.78%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.1%
Gross Margin
47%
Oper. Margin
19%
Profit Margin
14%
Payout
53%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.88-11.09
52W High
-32.27%
52W Low
+49%
RSI
43.95
Rel Volume
0.43
Avg Volume
14.36M
Volume
6.11M
Perf Week
-4.36%
Perf Month
-1.84%
Perf Quarter
-12.66%
Perf Half Y
-22.96%
-
-
-
-
Beta
0.109
-
-
Volatility
0.17%, 0.35%
Prev Close
0.68%
Price
7.45
Change
-0.67%
002349.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.63 | 1.42 | 1.57 | 1.67 | 1.93 | |
| Net income per share | 0.28 | -0.64 | 0.03 | 0.2 | 0.26 | |
| Operating cash flow per share | 0.1 | 0.35 | 0.4 | 0.38 | 0.44 | |
| Free cash flow per share | -0.09 | 0.04 | 0.26 | 0.28 | 0.36 | |
| Cash per share | 0.24 | 0.41 | 0.85 | 1.06 | 1.3 | |
| Book value per share | 2.74 | 2.27 | 2.59 | 2.75 | 2.95 | |
| Tangible book value per share | 2.27 | 2.2 | 2.66 | 2.77 | 2.94 | |
| Share holders equity per share | 2.74 | 2.27 | 2.59 | 2.75 | 2.95 | |
| Interest debt per share | 0.51 | 0.66 | 0.39 | 0.25 | 0.04 | |
| Market cap | 4.68B | 3.65B | 3.99B | 9.18B | 9.84B | |
| Enterprise value | 4.88B | 3.86B | 3.71B | 8.73B | 8.92B | |
| P/E ratio | 20.38 | -6.96 | 142.86 | 57.15 | 46.34 | |
| Price to sales ratio | 3.46 | 3.15 | 3.11 | 6.76 | 6.25 | |
| POCF ratio | 56.11 | 12.78 | 12.15 | 30.06 | 27.44 | |
| PFCF ratio | -60.94 | 121.43 | 19.02 | 40.81 | 33.14 | |
| P/B Ratio | 2.05 | 1.97 | 1.89 | 4.11 | 4.1 | |
| PTB ratio | 2.05 | 1.97 | 1.89 | 4.11 | 4.1 | |
| EV to sales | 3.6 | 3.33 | 2.89 | 6.43 | 5.67 | |
| Enterprise value over EBITDA | 12.07 | 16.98 | 10.49 | 28.68 | 22.86 | |
| EV to operating cash flow | 58.54 | 13.52 | 11.29 | 28.56 | 24.9 | |
| EV to free cash flow | -63.58 | 128.43 | 17.66 | 38.78 | 30.07 | |
| Earnings yield | 0.05 | -0.14 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | -0.02 | 0.01 | 0.05 | 0.02 | 0.03 | |
| Debt to equity | 0.18 | 0.28 | 0.14 | 0.09 | 0.01 | |
| Debt to assets | 0.12 | 0.17 | 0.09 | 0.06 | 0.01 | |
| Net debt to EBITDA | 0.5 | 0.93 | -0.81 | -1.5 | -2.33 | |
| Current ratio | 2.42 | 1.99 | 2.69 | 2.64 | 4.38 | |
| Interest coverage | 29.73 | 5.72 | 13.7 | 13.95 | 37.01 | |
| Income quality | 0.32 | -0.54 | 11.75 | 2.18 | 1.69 | |
| Dividend Yield | 0.01 | 0.02 | 0.01 | 0 | 0.01 | |
| Payout ratio | 0.25 | -0.12 | 0.71 | 0.28 | 0.25 | |
| Sales general and administrative to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.03 | 0.07 | 0.04 | 0.06 | 0.06 | |
| Intangibles to total assets | 0.24 | 0.12 | 0.1 | 0.1 | 0.08 | |
| Capex to operating cash flow | -1.92 | -0.89 | -0.36 | -0.26 | -0.17 | |
| Capex to revenue | -0.12 | -0.22 | -0.09 | -0.06 | -0.04 | |
| Capex to depreciation | -2.04 | -3.14 | -1.41 | -0.79 | -0.56 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.12 | 5.74 | 1.41 | 3.49 | 4.16 | |
| ROIC | 0.1 | 0.06 | 0.05 | 0.06 | 0.09 | |
| Return on tangible assets | 0.09 | -0.2 | 0.01 | 0.06 | 0.08 | |
| Graham Net | 0.15 | 0 | 0.59 | 0.86 | 1.31 | |
| Working capital | 714.99M | 548.49M | 892.17M | 991.83M | 1.33B | |
| Tangible asset value | 1.89B | 1.79B | 2.17B | 2.25B | 2.39B | |
| Net current asset value | 514.31M | 309.05M | 751.36M | 966.53M | 1.31B | |
| Invested capital | 0.18 | 0.28 | 0.14 | 0.09 | 0.01 | |
| Average receivables | 453.36M | 461M | 389.2M | 402.79M | 382.28M | |
| Average payables | 142.05M | 115.68M | 145.22M | 196.83M | 176.33M | |
| Average inventory | 430.82M | 395.89M | 327.06M | 315.45M | 315.39M | |
| Days sales outstanding | 147.34 | 118.3 | 114.87 | 108.14 | 84.05 | |
| Days payables outstanding | 63.01 | 63.52 | 99.53 | 107.16 | 60.81 | |
| Days of inventory on hand | 230.98 | 200.29 | 169.61 | 162.52 | 134.02 | |
| Receivables turnover | 2.48 | 3.09 | 3.18 | 3.38 | 4.34 | |
| Payables turnover | 5.79 | 5.75 | 3.67 | 3.41 | 6 | |
| Inventory turnover | 1.58 | 1.82 | 2.15 | 2.25 | 2.72 | |
| ROE | 0.1 | -0.28 | 0.01 | 0.07 | 0.09 | |
| Capex per share | -0.19 | -0.31 | -0.15 | -0.1 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.47 | 0.49 | 0.51 | 0.47 | 0.4 | |
| Net income per share | 0.05 | 0.03 | 0.11 | 0.08 | 0.05 | |
| Operating cash flow per share | 0.05 | 0.03 | 0.11 | 0.13 | 0.12 | |
| Free cash flow per share | 0.03 | 0 | 0.1 | 0.12 | 0.11 | |
| Cash per share | 1.12 | 1.3 | 1.29 | 1.29 | 1.41 | |
| Book value per share | 2.9 | 2.95 | 3.06 | 3.06 | 3.11 | |
| Tangible book value per share | 2.97 | 2.94 | 3.06 | 3.04 | 3.1 | |
| Share holders equity per share | 2.9 | 2.95 | 3.06 | 3.06 | 3.11 | |
| Interest debt per share | 0.1 | 0.03 | 0.03 | 0.01 | 0.03 | |
| Market cap | 8.96B | 9.84B | 8.71B | 7.35B | 7.79B | |
| Enterprise value | 8.32B | 8.92B | 7.81B | 6.61B | 6.97B | |
| P/E ratio | 57.77 | 107.29 | 24.84 | 27.46 | 47.81 | |
| Price to sales ratio | 23.38 | 24.71 | 20.92 | 19.4 | 24.03 | |
| POCF ratio | 231.07 | 429.15 | 99.37 | 69.97 | 81.01 | |
| PFCF ratio | 370.71 | 10.06K | 108.96 | 74.23 | 88.43 | |
| P/B Ratio | 3.8 | 4.1 | 3.5 | 2.95 | 3.08 | |
| PTB ratio | 3.8 | 4.1 | 3.5 | 2.95 | 3.08 | |
| EV to sales | 21.69 | 22.42 | 18.76 | 17.45 | 21.49 | |
| Enterprise value over EBITDA | 127.98 | 356.19 | 65.22 | 76.05 | 133.92 | |
| EV to operating cash flow | 214.42 | 389.42 | 89.1 | 62.92 | 72.48 | |
| EV to free cash flow | 344 | 9.13K | 97.7 | 66.76 | 79.11 | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0.04 | 0.01 | 0.01 | 0 | 0.01 | |
| Debt to assets | 0.03 | 0.01 | 0.01 | 0 | 0.01 | |
| Net debt to EBITDA | -9.94 | -36.34 | -7.52 | -8.51 | -15.77 | |
| Current ratio | 3.56 | 4.38 | 5.22 | 5.26 | 5.37 | |
| Interest coverage | 30.54 | 21.6 | 140.69 | 179.72 | 87.43 | |
| Income quality | 1 | 1 | 1 | 1.57 | 2.36 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0.08 | 0.96 | 0 | 1.38 | 0 | |
| Sales general and administrative to revenue | 0.23 | -0.16 | 0.06 | -0.03 | 0.22 | |
| Research and developement to revenue | 0.04 | 0.1 | 0.03 | 0.04 | 0.05 | |
| Intangibles to total assets | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | |
| Capex to operating cash flow | -0.38 | -0.96 | -0.09 | -0.06 | -0.08 | |
| Capex to revenue | -0.04 | -0.06 | -0.02 | -0.02 | -0.02 | |
| Capex to depreciation | -0.85 | -1.28 | -0.4 | -0.31 | 0.19 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.76 | 1.37 | 2.72 | 2.38 | 1.87 | |
| ROIC | 0.02 | 0.01 | 0.04 | 0.03 | 0.02 | |
| Return on tangible assets | 0.01 | 0.01 | 0.03 | 0.02 | 0.01 | |
| Graham Net | 1.1 | 1.31 | 1.43 | 1.43 | 1.52 | |
| Working capital | 1.19B | 1.33B | 1.46B | 1.45B | 1.52B | |
| Tangible asset value | 2.42B | 2.39B | 2.49B | 2.48B | 2.52B | |
| Net current asset value | 1.17B | 1.31B | 1.43B | 1.43B | 1.49B | |
| Invested capital | 0.04 | 0.01 | 0.01 | 0 | 0.01 | |
| Average receivables | 417.57M | 390.57M | 398.41M | 424.96M | 411M | |
| Average payables | 165.15M | 150.29M | 141.78M | 157.62M | 164.92M | |
| Average inventory | 338.86M | 319.99M | 311.57M | 318.02M | 311.96M | |
| Days sales outstanding | 98.31 | 81.91 | 93.94 | 98.64 | 112.85 | |
| Days payables outstanding | 71.56 | 55.42 | 62.74 | 77.44 | 84.12 | |
| Days of inventory on hand | 147.75 | 122.13 | 137.5 | 144.93 | 160.95 | |
| Receivables turnover | 0.92 | 1.1 | 0.96 | 0.91 | 0.8 | |
| Payables turnover | 1.26 | 1.62 | 1.43 | 1.16 | 1.07 | |
| Inventory turnover | 0.61 | 0.74 | 0.65 | 0.62 | 0.56 | |
| ROE | 0.02 | 0.01 | 0.04 | 0.03 | 0.02 | |
| Capex per share | -0.02 | -0.03 | -0.01 | -0.01 | -0.01 |
002349.SZ Frequently Asked Questions
What is Jinghua Pharmaceutical Group Co., Ltd. stock symbol ?
Jinghua Pharmaceutical Group Co., Ltd. is a CN stock and trading under the symbol 002349.SZ
What is Jinghua Pharmaceutical Group Co., Ltd. stock quote today ?
Jinghua Pharmaceutical Group Co., Ltd. stock price is $7.45 today.
Is Jinghua Pharmaceutical Group Co., Ltd. stock public?
Yes, Jinghua Pharmaceutical Group Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 14.36M
- Market Capitalization 6.13B
- Employee 1.64K
- CEO Mr. Yunzhong Zhou
- Headquarters Nantong,CN
- IPO Date 2010-02-03
-
Website
https://www.jinghuapharm.com 
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.
